Therapy Areas: Infectious Diseases
Curative Biotechnology licenses IMT504 from Mid-Atlantic BioTherapeutics for development of COVID-19 Vaccine
8 October 2021 -

Curative Biotechnology Inc (OTC:CUBT) on Thursday signed an agreement with Mid-Atlantic BioTherapeutics (MABT) to broaden its license to novel patented immunotherapy and adjuvant of IMT504 to include the development of a next generation COVID-19 vaccine.

The company has acquired the worldwide rights for the development of IMT504 from Mid-Atlantic BioTherapeutics.

Under the partnership, the companies will develop a next generation COVID-19 vaccine targeted to meet the needs of this vulnerable kidney failure patient population. A consequence of kidney failure is the loss of a robust immunologic response to infections, including COVID-19. The kidney failure patients may get a more severe version of COVID-19 that could lead to a greater chance of hospitalization or even death.

Previously, Curative Biotech had acquired the worldwide rights for the development of IMT504 to treat symptomatic rabies.

Utilizing IMT504 as an adjuvant on top of a proprietary protein vaccine, this new license adds a second infectious disease programme to the Curative Biotech product development portfolio.



Related Headlines